Phase II study into Riociguat with pulmonary hypertension.

• Research type

  Research Study

• Full title

  Randomized, double blind, placebo controlled, parallel group, multi-center study to evaluate the hemodynamic effects of Riociguat (BAY 63 2521) as well as safety and kinetics in patients with pulmonary hypertension associated with left ventricular systolic dysfunction

• IRAS ID

  59885

• Contact name

  Jayan Parameshwar

• Sponsor organisation

  Bayer plc

• Eudract number

  2009-015878-35

• Clinicaltrials.gov Identifier

  NCT01065454

• Research summary

  The aim of this study is to assess whether increasing oral doses of Riociguat are safe and improve the well-being, symptoms and outcome in patients with pulmonary hypertension associated with left ventriculareasystolic dysfunction.

• REC name

  North East - York Research Ethics Committee

• REC reference

  10/H0903/46

• Date of REC Opinion

  15 Oct 2010

• REC opinion

  Favourable Opinion